Related Experiment Video
Updated: Sep 14, 2025
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
The function of CD164 in breast cancer and its possibility as a molecular biomarker: bioinformatics analysis and
Mengxin Li1, Juanjuan Mao2, Guang Wang1
1Department of Breast Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China.
Background:
Breast cancer is the most prevalent malignancy among women globally. Molecular-targeted therapy improves treatment efficacy by precisely targeting tumor-specific molecules, minimizing damage to healthy tissues. Identifying new molecular targets is essential for enhancing therapeutic outcomes and prognosis in breast cancer.
Methods:
The TCGA database was used to assess CD164 expression in breast cancer and its correlation with prognosis. Chemosensitivity analysis was performed to evaluate the association between CD164 and response to targeted therapies. Immune infiltration analysis was conducted to assess the relationship between CD164 expression and immune cell populations. CCK-8 assays, clonogenic assays, and flow cytometry analyses were employed to examine the effects of CD164 knockdown on cell viability, proliferation, cell cycle progression, and apoptosis. RNA sequencing and Gene Set Enrichment Analysis (GSEA) were performed to identify pathways regulated by CD164.
Results:
CD164 was highly expressed in breast cancer tissues and correlated with poorer prognosis, including shorter disease-free and overall survival. Chemosensitivity analysis linked CD164 to sensitivity to multiple targeted therapies, suggesting its role in oncogenic pathways. Immune infiltration analysis revealed CD164's association with immunosuppressive cells, including resting CD4 memory T cells, M2 macrophages, and mast cells, while exhibiting a negative correlation with Tregs and NK cells, underscoring its significance in the immunosuppressive tumor microenvironment. CD164 knockdown inhibited cell viability and proliferation and induced cell cycle arrest and apoptosis. RNA sequencing and GSEA showed that CD164 regulates proliferation, metabolism, migration, and adhesion pathways while suppressing tumor-promoting pathways and activating immune-related pathways.
Conclusions:
CD164 plays a critical role in breast cancer progression, influencing tumor growth, immune evasion, and therapeutic response. It represents a promising therapeutic target, offering potential for improving breast cancer treatment and prognosis.
Insights
CD164 is highly expressed in breast cancer, correlating with poor prognosis and influencing therapeutic response. Targeting CD164 may improve breast cancer treatment outcomes and patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Breast cancer is a leading global malignancy in women.
- Molecular-targeted therapies enhance treatment efficacy by targeting tumor-specific molecules.
- Identifying novel molecular targets is crucial for improving breast cancer outcomes.
Purpose of the Study:
- To investigate the role of CD164 in breast cancer progression.
- To assess the correlation of CD164 expression with patient prognosis and response to targeted therapies.
- To explore the impact of CD164 on the tumor microenvironment and cellular processes.
Main Methods:
- Utilized The Cancer Genome Atlas (TCGA) database for expression analysis.
- Performed chemosensitivity, immune infiltration, CCK-8, clonogenic, and flow cytometry assays.
- Conducted RNA sequencing and Gene Set Enrichment Analysis (GSEA) to identify regulated pathways.
Main Results:
- CD164 expression is elevated in breast cancer and linked to poorer prognosis and survival.
- CD164 influences sensitivity to targeted therapies and is associated with an immunosuppressive tumor microenvironment.
- CD164 knockdown inhibits cell viability and proliferation, inducing cell cycle arrest and apoptosis.
Conclusions:
- CD164 is a critical factor in breast cancer progression, affecting tumor growth, immune evasion, and treatment response.
- CD164 represents a promising therapeutic target for enhancing breast cancer treatment strategies.
- Targeting CD164 holds potential for improving patient prognosis and therapeutic outcomes.
